A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DRM / drug resistance mutations

[Related PubMed/MEDLINE]
Total Number of Papers: 53
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DRM  (>> Co-occurring Abbreviation)
Long Form:   drug resistance mutations
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A 28-Year History of HIV-1 Drug Resistance and Transmission in Washington, DC. ---
2019 Antiretroviral adherence, elevated viral load and drug resistant mutations in HIV-infected women initiating treatment in pregnancy: a nested case-control study. ART, CI, OR, VL
2019 Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. ART, HIV-1
2018 Analysis of drug resistance mutations in whole blood DNA from HIV-1 infected patients by single genome and ultradeep sequencing analysis. SGRT, SGS, UDP, wbDNA
2018 Characterisation of HIV-1 transmission clusters and drug-resistant mutations in Denmark, 2004 to 2016. HIV, LP, MSM, SDRM
2018 Effect of HIV/HCV Co-Infection on the Protease Evolution of HIV-1B: A Pilot Study in a Pediatric Population. ART, dS, HIV-1BPR
2018 High Prevalence of HIV Drug Resistance Among Newly Diagnosed Infants Aged <18 Months: Results From a Nationwide Surveillance in Nigeria. NNRTI, PMTCT
2018 HIV drug resistance following a decade of the free antiretroviral therapy programme in India: A review. ART, NNRTI, NRTI, RT
2018 The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen. ART, CD4, NRTI, PCA, RT, VF
10  2018 Trends in Drug Resistance Prevalence, HIV-1 Variants and Clinical Status in HIV-1-infected Pediatric Population in Madrid: 1993 to 2015 Analysis. NNRTI, NRTI
11  2017 Characterization of HIV diversity, phylodynamics and drug resistance in Washington, DC. ---
12  2017 Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. GRT, HIVDB, INSTI, IS, NNRTI, NRTI, PI
13  2017 Drug resistance in antiretroviral-naive children newly diagnosed with HIV-1 in Manaus, Amazonas. PMTCT, TDR
14  2017 Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients. ART, VF, VL
15  2017 High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa. cART, PR, RT, TAMs
16  2017 HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa. NNRTI, VL
17  2017 HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. HIV-1, NNRTIs, SDRMs, TDR, WHO
18  2017 Identifications of drug resistance mutations among antiretroviral treatment naive HIV-1 patients in Peninsular Malaysia. NNRTI, NRTI, PIs
19  2017 Impact of Clinical Parameters in the Intrahost Evolution of HIV-1 Subtype B in Pediatric Patients: A Machine Learning Approach. HIV-1B, PI
20  2017 Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014. ---
21  2017 Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options. ART, HIV, NRTI, VF, VL
22  2017 No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men. BF, RT
23  2016 HIV-1 Variants and Drug Resistance in Pregnant Women from Bata (Equatorial Guinea): 2012-2013. ADR, ART, cART, DBS, NNRTI, NRTI, PI, TDR
24  2016 Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230. ETV, NNRTI, PR, RPV, RT, SE, VF
25  2016 Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk. ---
26  2015 Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061. ARV, HPTN
27  2015 HIV-1 subtype B/B' and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China. TDR
28  2015 Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia. ART, LLV
29  2015 Short Communication: In Vitro Accumulation of Drug Resistance Mutations in Chimeric Infectious Clones Containing Subtype B or C Reverse Transcriptase and Selected with Tenofovir or Didanosine. ddI, HAART, TDF
30  2015 Transmitted Drug Resistance Among Recently Diagnosed Adults and Children in Sao Paulo, Brazil. NNRTI, TDRM
31  2015 Use of Dried Plasma Spots for HIV-1 Viral Load Determination and Drug Resistance Genotyping in Mexican Patients. DPS, VL
32  2014 Antiretroviral treatment outcome in HIV-1-infected patients routinely followed up in capital cities and remote areas of Senegal, Mali and Guinea-Conakry. ART, CI, DBS, RLS, VF, VL
33  2014 Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review. ART, HIVDR, TDR
34  2014 Early selection of resistance-associated mutations in HIV-1 RT C-terminal domains across different subtypes: role of the genetic barrier to resistance. RT, RTI
35  2014 Incidence of transmitted antiretroviral drug resistance in treatment-naive HIV-1-infected persons in a large South Central United States clinic. SDRM, TDR, WHO
36  2014 Profile of the HIV epidemic in Cape Verde: molecular epidemiology and drug resistance mutations among HIV-1 and HIV-2 infected patients from distinct islands of the archipelago. ARTn, TDRM
37  2014 Short communication: Prevalence of HIV-1 transmitted drug resistance in Liberia. NNRTI, NRTI, RT, TDR
38  2013 Stable HIV-1 integrase diversity during initial HIV-1 RNA decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy. RAL
39  2012 Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1. ART, NNRTI, NRTI, PBMC, PI
40  2012 HIV-1 genetic diversity and transmitted drug resistance mutations among patients from the North, Central and South regions of Angola. ---
41  2012 Mycobacterium tuberculosis "Beijing" epidemics: a race against mutations? ---
42  2012 Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. HAART, RT, UDPS
43  2012 Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing. UDS, VF
44  2011 Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. AM, ART, CI, UDS
45  2011 Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. ART, VL
46  2011 Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure. HIV-1, NNRTI, PI
47  2010 Frequency of primary resistance to antiretroviral drugs and genetic variability of HIV-1 among infected pregnant women recently diagnosed in Luanda-Angola. PI
48  2010 Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women. ---
49  2009 Human immunodeficiency virus-1 genotypic drug resistance among volunteer blood donors in Yunnan, China. CRF, HIV-1, PI
50  2008 Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART. GRT, pVL
51  2008 The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. IAS, SDRM, THDR
52  2004 Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. ART, GSS, VL
53  2003 Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations. QAPs